Palvella Therapeutics
PVLAPalvella Therapeutics Inc. (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company based in the United States. The company's business is centered on the development and commercialization of targeted therapies for patients with rare, genetic dermatological conditions characterized by significant unmet medical need. Its operations are focused within the biotech and dermatology sectors. The company's lead product candidate is QTORIN™ 3.9% rapamycin anhydrous gel, which is being developed for the treatment of pachyonychia congenita (PC) and other rare keratin disorders. Pachyonychia congenita is a debilitating genetic skin disease that causes painful plantar keratoderma and blistering. Palvella has reported positive data from its Phase 3 VALO study for QTORIN rapamycin gel in PC and is advancing its clinical development program. Palvella Therapeutics is a publicly traded entity, and its common stock is listed on the Nasdaq Global Market under the ticker symbol "PVLA." The company's pipeline and strategic efforts are dedicated to addressing specific, well-defined genetic skin diseases through its proprietary formulation platform.
PVLA · Stock Price
Historical price data
About
Palvella Therapeutics Inc. (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company based in the United States. The company's business is centered on the development and commercialization of targeted therapies for patients with rare, genetic dermatological conditions characterized by significant unmet medical need. Its operations are focused within the biotech and dermatology sectors. The company's lead product candidate is QTORIN™ 3.9% rapamycin anhydrous gel, which is being developed for the treatment of pachyonychia congenita (PC) and other rare keratin disorders. Pachyonychia congenita is a debilitating genetic skin disease that causes painful plantar keratoderma and blistering. Palvella has reported positive data from its Phase 3 VALO study for QTORIN rapamycin gel in PC and is advancing its clinical development program. Palvella Therapeutics is a publicly traded entity, and its common stock is listed on the Nasdaq Global Market under the ticker symbol "PVLA." The company's pipeline and strategic efforts are dedicated to addressing specific, well-defined genetic skin diseases through its proprietary formulation platform.